Second pharma deal further validates Interprotein's discovery technology
This article was originally published in Scrip
Executive Summary
The Japanese drug discovery venture Interprotein Corp has entered into its second agreement with a major pharma firm in as many months, this time with Takeda for the discovery and optimisation of small molecule inhibitors of protein-protein interaction.